Handel Illumina Inc - ILMN CFD
Føj til favorit- Opsummering
- Historisk Data
- Begivenheder
- Resultatopgørelse
- Saldo
- Cash flow
- Ejerskab
Spænd | 0.44 | ||||||||
Long position, gebyr natten over
Long position overnight fee
Gå til platform | -0.030779% | ||||||||
Short position, gebyr natten over
Short position overnight fee
Gå til platform | -0.013666% | ||||||||
Gebyr natten over, tid | 22:00 (UTC) | ||||||||
Min. handlet mængde | 1 | ||||||||
Valuta | USD | ||||||||
Margen | 20% | ||||||||
Aktiebørs | United States of America | ||||||||
Kommission på handel | 0% |
*Information provided by Capital.com
Illumina Inc ESG Risk Ratings
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Tidligere luk* | 224.67 |
Åben* | 218.47 |
1-Års Ændring* | -38.6% |
Dagens Spænd* | 213.21 - 219.92 |
52-Ugers Spænd | 173.45-371.16 |
Gennemsnitlig Volumen (10 dage) | 985.98K |
Gennemsnitlig Volumen (3 måneder) | 24.08M |
Market Cap | 33.70B |
P/E-forhold | -100.00K |
Udestående aktier | 157.30M |
Omsætning | 4.70B |
EPS | -26.46 |
Dividend (Udbytte %) | N/A |
Beta | 1.14 |
Næste indtjeningsopgørelse | Feb 7, 2023 |
Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Luk | Change | Change (%) | Åben | High | Low |
---|---|---|---|---|---|---|
Feb 3, 2023 | 214.17 | -5.51 | -2.51% | 219.68 | 220.98 | 212.65 |
Feb 2, 2023 | 224.67 | 6.15 | 2.81% | 218.52 | 225.28 | 215.72 |
Feb 1, 2023 | 216.12 | 5.51 | 2.62% | 210.61 | 217.50 | 207.94 |
Jan 31, 2023 | 214.00 | 4.87 | 2.33% | 209.13 | 214.33 | 208.89 |
Jan 30, 2023 | 209.95 | 2.26 | 1.09% | 207.69 | 213.97 | 207.69 |
Jan 27, 2023 | 213.81 | 4.68 | 2.24% | 209.13 | 214.90 | 206.56 |
Jan 26, 2023 | 212.57 | 0.71 | 0.34% | 211.86 | 214.95 | 209.51 |
Jan 25, 2023 | 210.75 | 2.76 | 1.33% | 207.99 | 211.78 | 204.96 |
Jan 24, 2023 | 215.07 | 0.92 | 0.43% | 214.15 | 217.89 | 212.09 |
Jan 23, 2023 | 216.12 | 12.49 | 6.13% | 203.63 | 216.55 | 202.39 |
Jan 20, 2023 | 204.12 | 7.97 | 4.06% | 196.15 | 204.69 | 193.87 |
Jan 19, 2023 | 196.19 | -7.13 | -3.51% | 203.32 | 205.72 | 195.96 |
Jan 18, 2023 | 205.62 | -1.94 | -0.93% | 207.56 | 212.03 | 203.70 |
Jan 17, 2023 | 206.23 | 5.70 | 2.84% | 200.53 | 206.45 | 196.95 |
Jan 13, 2023 | 200.81 | 10.86 | 5.72% | 189.95 | 201.53 | 189.71 |
Jan 12, 2023 | 193.65 | -7.04 | -3.51% | 200.69 | 202.53 | 189.27 |
Jan 11, 2023 | 203.81 | 6.79 | 3.45% | 197.02 | 204.44 | 193.97 |
Jan 10, 2023 | 194.39 | 9.69 | 5.25% | 184.70 | 199.41 | 180.82 |
Jan 9, 2023 | 207.21 | 2.84 | 1.39% | 204.37 | 210.67 | 203.57 |
Jan 6, 2023 | 201.61 | -1.66 | -0.82% | 203.27 | 203.30 | 189.81 |
Illumina Inc Events
Time (UTC) | Country | Event |
---|---|---|
No events scheduled |
- Årlig
- Pr kvartal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Total omsætning | 2398.37 | 2752 | 3333 | 3543 | 3239 | 4526 |
Omsætning | 2398.37 | 2752 | 3333 | 3543 | 3239 | 4526 |
Kost af omsætning, Total | 731.925 | 908 | 1033 | 1076 | 1036 | 1372 |
Bruttofortjeneste | 1666.45 | 1844 | 2300 | 2467 | 2203 | 3154 |
Totale Driftsudgifter | 1811.34 | 2146 | 2450 | 2504 | 2659 | 4649 |
Salgs/Generelle/Admin. Udgifter, Total | 583.005 | 674 | 794 | 835 | 941 | 2092 |
Forskning & Udvikling | 504.415 | 541 | 623 | 647 | 682 | 1185 |
Usædvanlig Udgift (Indkomst) | -8.004 | 23 | 0 | -54 | ||
Driftsindtægter | 587.032 | 606 | 883 | 1039 | 580 | -123 |
Renteindkomst (Udgift), Netto Ikke-Drift | -23.382 | 435 | 8 | 75 | 237 | 919 |
Andre, Netto | -2.472 | 2 | 3 | 4 | 39 | 88 |
Netto Indkomst Før Skat | 561.178 | 1043 | 894 | 1118 | 856 | 884 |
Netto Indkomst Efter Skat | 428.09 | 828 | 793 | 990 | 656 | 762 |
Minoritetsrente | 34.559 | 48 | 44 | 12 | 0 | |
Netto Indkomst Før Ekstra Ting | 462.649 | 876 | 837 | 1002 | 656 | 762 |
Netto Indkomst | 462.649 | 726 | 826 | 1002 | 656 | 762 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 462.649 | 876 | 837 | 1002 | 656 | 762 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 462.649 | 726 | 826 | 1002 | 656 | 762 |
Fortyndet Netto Indkomst | 462.649 | 726 | 826 | 1002 | 656 | 762 |
Fortyndet Vægtet Gennemsnit Aktier | 148.04 | 148 | 149 | 149 | 148 | 151 |
Fortyndet EPS Uden Ekstraordinære Ting | 3.12516 | 5.91892 | 5.61745 | 6.72483 | 4.43243 | 5.04636 |
Dividends per Share - Common Stock Primary Issue | 0 | |||||
Fortyndet Normaliseret EPS | 3.08392 | 6.04229 | 5.61745 | 6.40391 | 4.43243 | 5.04636 |
Totale Ekstraordinære Ting | -150 | -11 |
Q1 2021 | Q2 2021 | Q3 2021 | Q4 2022 | Q1 2022 | |
---|---|---|---|---|---|
Total omsætning | 1093 | 1126 | 1108 | 1199 | 1223 |
Omsætning | 1093 | 1126 | 1108 | 1199 | 1223 |
Kost af omsætning, Total | 329 | 324 | 338 | 382 | 408 |
Bruttofortjeneste | 764 | 802 | 770 | 817 | 815 |
Totale Driftsudgifter | 900 | 939 | 1653 | 1158 | 1039 |
Salgs/Generelle/Admin. Udgifter, Total | 374 | 413 | 879 | 426 | 308 |
Forskning & Udvikling | 197 | 202 | 436 | 350 | 323 |
Driftsindtægter | 193 | 187 | -545 | 41 | 184 |
Renteindkomst (Udgift), Netto Ikke-Drift | -64 | -12 | 931 | 64 | -50 |
Andre, Netto | 40 | 32 | 34 | -19 | 6 |
Netto Indkomst Før Skat | 169 | 207 | 420 | 86 | 140 |
Netto Indkomst Efter Skat | 147 | 185 | 317 | 112 | 86 |
Netto Indkomst Før Ekstra Ting | 147 | 185 | 317 | 112 | 86 |
Netto Indkomst | 147 | 185 | 317 | 112 | 86 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 147 | 185 | 317 | 112 | 86 |
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting | 147 | 185 | 317 | 112 | 86 |
Fortyndet Netto Indkomst | 147 | 185 | 317 | 112 | 86 |
Fortyndet Vægtet Gennemsnit Aktier | 147 | 147 | 153 | 157 | 159 |
Fortyndet EPS Uden Ekstraordinære Ting | 1 | 1.2585 | 2.0719 | 0.71338 | 0.54088 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Fortyndet Normaliseret EPS | 1 | 1.2585 | 2.0719 | 0.71338 | 0.54088 |
- Årlig
- Pr kvartal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Totale Nuværende Aktiver | 2318.09 | 2980 | 4490 | 4451 | 4483 | 2713 |
Likvider og Kortsigtede Investeringer | 1558.72 | 2145 | 3512 | 3414 | 3472 | 1339 |
Likvider & Lignende | 734.516 | 1225 | 1144 | 2042 | 1810 | 1232 |
Kortsigtede Investeringer | 824.208 | 920 | 2368 | 1372 | 1662 | 107 |
Totale Tilgodehavender, Netto | 381.316 | 411 | 514 | 573 | 487 | 648 |
Accounts Receivable - Trade, Net | 380.93 | 411 | 514 | 573 | 487 | 648 |
Total Inventory | 300.17 | 333 | 386 | 359 | 372 | 431 |
Prepaid Expenses | 77.881 | 91 | 78 | 105 | 152 | 295 |
Total Assets | 4280.6 | 5257 | 6959 | 7316 | 7585 | 15217 |
Property/Plant/Equipment, Total - Net | 713.334 | 931 | 1075 | 1444 | 1454 | 1696 |
Property/Plant/Equipment, Total - Gross | 1040.15 | 1347 | 1596 | 2012 | 2132 | 2492 |
Accumulated Depreciation, Total | -326.813 | -416 | -521 | -568 | -678 | -796 |
Goodwill, Net | 775.995 | 771 | 831 | 824 | 897 | 7113 |
Intangibles, Net | 242.652 | 175 | 185 | 145 | 142 | 3250 |
Other Long Term Assets, Total | 230.528 | 400 | 378 | 452 | 609 | 445 |
Total Current Liabilities | 704.665 | 746 | 1804 | 665 | 1244 | 1093 |
Accounts Payable | 137.93 | 160 | 184 | 149 | 192 | 332 |
Accrued Expenses | 392.296 | 376 | 256 | 263 | 287 | 429 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1.25 | 10 | 1107 | 0 | 511 | 0 |
Other Current Liabilities, Total | 173.189 | 200 | 257 | 253 | 254 | 332 |
Total Liabilities | 2083.37 | 2508 | 3201 | 2703 | 2891 | 4477 |
Total Long Term Debt | 1047.81 | 1182 | 890 | 1141 | 673 | 1695 |
Long Term Debt | 1047.81 | 1182 | 890 | 1141 | 673 | 1695 |
Minority Interest | 116.946 | 220 | 148 | 0 | ||
Other Liabilities, Total | 213.955 | 360 | 359 | 897 | 974 | 1689 |
Total Equity | 2197.23 | 2749 | 3758 | 4613 | 4694 | 10740 |
Common Stock | 1.887 | 2 | 2 | 2 | 2 | 2 |
Additional Paid-In Capital | 2733.39 | 2833 | 3290 | 3560 | 3815 | 8938 |
Retained Earnings (Accumulated Deficit) | 1485.41 | 2256 | 3083 | 4067 | 4723 | 5485 |
Treasury Stock - Common | -2022.43 | -2341 | -2616 | -3021 | -3848 | -3702 |
Unrealized Gain (Loss) | -2.326 | -2 | -2 | 4 | 1 | |
Other Equity, Total | 1.289 | 1 | 1 | 1 | 1 | 17 |
Total Liabilities & Shareholders’ Equity | 4280.6 | 5257 | 6959 | 7316 | 7585 | 15217 |
Total Common Shares Outstanding | 146.196 | 147 | 147 | 147 | 146 | 157 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 |
Apr 2021 | Jul 2021 | Oct 2021 | Jan 2022 | Apr 2022 | |
---|---|---|---|---|---|
Totale Nuværende Aktiver | 5642 | 5310 | 2451 | 2713 | 2755 |
Likvider og Kortsigtede Investeringer | 4630 | 4286 | 1265 | 1339 | 1416 |
Likvider & Lignende | 4433 | 4196 | 1080 | 1232 | 1351 |
Kortsigtede Investeringer | 197 | 90 | 185 | 107 | 65 |
Totale Tilgodehavender, Netto | 517 | 540 | 604 | 648 | 630 |
Accounts Receivable - Trade, Net | 517 | 540 | 604 | 648 | 630 |
Total Inventory | 364 | 380 | 401 | 431 | 465 |
Prepaid Expenses | 131 | 104 | 181 | 295 | 244 |
Total Assets | 8755 | 8675 | 15063 | 15217 | 15274 |
Property/Plant/Equipment, Total - Net | 1444 | 1481 | 1685 | 1696 | 1740 |
Goodwill, Net | 897 | 966 | 7098 | 7113 | 7113 |
Intangibles, Net | 134 | 162 | 3351 | 3250 | 3209 |
Other Long Term Assets, Total | 638 | 756 | 478 | 445 | 233 |
Total Current Liabilities | 1268 | 874 | 914 | 1093 | 1490 |
Accounts Payable | 178 | 200 | 248 | 332 | 291 |
Accrued Expenses | 298 | 365 | 391 | 429 | 377 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 488 | 0 | 0 | 0 | 499 |
Other Current Liabilities, Total | 304 | 309 | 275 | 332 | 323 |
Total Liabilities | 3833 | 3495 | 4470 | 4477 | 4379 |
Total Long Term Debt | 1672 | 1679 | 1687 | 1695 | 1241 |
Long Term Debt | 1672 | 1679 | 1687 | 1695 | 1241 |
Other Liabilities, Total | 893 | 942 | 1869 | 1689 | 1648 |
Total Equity | 4922 | 5180 | 10593 | 10740 | 10895 |
Common Stock | 2 | 2 | 2 | 2 | 2 |
Additional Paid-In Capital | 3914 | 3993 | 8849 | 8938 | 8957 |
Retained Earnings (Accumulated Deficit) | 4870 | 5055 | 5372 | 5485 | 5632 |
Treasury Stock - Common | -3872 | -3878 | -3643 | -3702 | -3714 |
Other Equity, Total | 8 | 8 | 13 | 17 | 18 |
Total Liabilities & Shareholders’ Equity | 8755 | 8675 | 15063 | 15217 | 15274 |
Total Common Shares Outstanding | 146 | 146 | 157 | 157 | 157 |
Preferred Stock - Non Redeemable, Net | 0 | ||||
Long Term Investments | 224 |
- Årlig
- Pr kvartal
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | |
---|---|---|---|---|---|---|
Netto indkomst/Startlinje | 428 | 678 | 782 | 990 | 656 | 762 |
Likvider Fra Driftsaktiviteter | 779 | 875 | 1142 | 1051 | 1080 | 545 |
Likvider Fra Driftsaktiviteter | 90 | 110 | 140 | 151 | 156 | 176 |
Amortization | 51 | 46 | 39 | 37 | 31 | 75 |
Deferred Taxes | 94 | 81 | -18 | 11 | 117 | -76 |
Ikke-Likvide Ting | 161 | -235 | 217 | 56 | 47 | -240 |
Cash Taxes Paid | 60 | 149 | 99 | 164 | 119 | 233 |
Ændringer i Driftskapital | -45 | 195 | -18 | -194 | 73 | -152 |
Likvider fra Investeringsaktiviteter | -515 | -214 | -1813 | 745 | -554 | -1069 |
Kapitaludgifter | -271 | -312 | -296 | -209 | -189 | -208 |
Andre Investerings-Cash-Flow-Ting, Total | -244 | 98 | -1517 | 954 | -365 | -861 |
Likvider fra Financieringsaktiviteter | -296 | -176 | 594 | -897 | -766 | -51 |
Financiering af Cash-Flow-Ting | -33 | 8 | 18 | -82 | -91 | -582 |
Udstedelse (Pensionering) af Aktier, Netto | -202 | -180 | -155 | -265 | -675 | 60 |
Udstedelse (Pensionering) af Gæld, Netto | -61 | -4 | 731 | -550 | 0 | 471 |
Udenlandsk Børs Effekter | -2 | 5 | -4 | -1 | 8 | -3 |
Netto Ændring i Likviditet | -34 | 490 | -81 | 898 | -232 | -578 |
Apr 2021 | Jul 2021 | Oct 2021 | Jan 2022 | Apr 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | 147 | 333 | 650 | 762 | 86 |
Cash From Operating Activities | 282 | 535 | 263 | 545 | 172 |
Cash From Operating Activities | 41 | 82 | 128 | 176 | 50 |
Amortization | 7 | 15 | 34 | 75 | 41 |
Deferred Taxes | -79 | -156 | -81 | -76 | -21 |
Non-Cash Items | 104 | 167 | -301 | -240 | 81 |
Changes in Working Capital | 62 | 94 | -167 | -152 | -65 |
Cash From Investing Activities | 1376 | 1379 | -1069 | -1069 | -74 |
Capital Expenditures | -42 | -86 | -138 | -208 | -61 |
Other Investing Cash Flow Items, Total | 1418 | 1465 | -931 | -861 | -13 |
Cash From Financing Activities | 968 | 472 | 78 | -51 | 21 |
Financing Cash Flow Items | -24 | -30 | -452 | -582 | -12 |
Issuance (Retirement) of Stock, Net | 31 | 31 | 59 | 60 | 33 |
Issuance (Retirement) of Debt, Net | 961 | 471 | 471 | 471 | 0 |
Foreign Exchange Effects | -3 | 0 | -2 | -3 | 0 |
Net Change in Cash | 2623 | 2386 | -730 | -578 | 119 |
Investornavn | Investortype | Procent udestående | Aktiebeholdning | Aktieændring | Beholdningsdato | IOmsætningsscore |
---|---|---|---|---|---|---|
Baillie Gifford & Co. | Investment Advisor | 10.6441 | 16743103 | -2276998 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 8.1155 | 12765729 | 181808 | 2022-09-30 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.0067 | 7875617 | -70812 | 2022-09-30 | LOW |
Edgewood Management LLC | Investment Advisor/Hedge Fund | 4.7216 | 7427083 | -741779 | 2022-09-30 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.1761 | 6569010 | 87320 | 2022-09-30 | LOW |
Polen Capital Management, LLC | Investment Advisor/Hedge Fund | 2.8744 | 4521397 | 1731169 | 2022-09-30 | LOW |
Loomis, Sayles & Company, L.P. | Investment Advisor/Hedge Fund | 2.2875 | 3598290 | -133808 | 2022-09-30 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 2.1278 | 3347008 | 794245 | 2022-09-30 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7894 | 2814723 | 62313 | 2022-09-30 | LOW |
Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.334 | 2098412 | -202259 | 2022-12-31 | LOW |
Morgan Stanley Investment Management Inc. (US) | Investment Advisor/Hedge Fund | 1.224 | 1925400 | 809753 | 2022-09-30 | LOW |
Walter Scott & Partners Ltd. | Investment Advisor/Hedge Fund | 1.1659 | 1833973 | -210485 | 2022-09-30 | LOW |
Two Sigma Investments, LP | Hedge Fund | 1.1614 | 1826869 | 138559 | 2022-09-30 | HIGH |
Janus Henderson Investors | Investment Advisor/Hedge Fund | 1.1278 | 1773989 | 181237 | 2022-09-30 | LOW |
Nuveen LLC | Pension Fund | 1.0671 | 1678559 | 29844 | 2022-09-30 | LOW |
Veritas Asset Management LLP | Investment Advisor/Hedge Fund | 1.0116 | 1591247 | 27792 | 2022-09-30 | LOW |
AllianceBernstein L.P. | Investment Advisor/Hedge Fund | 1.001 | 1574624 | 671475 | 2022-09-30 | LOW |
Select Equity Group, L.P. | Investment Advisor/Hedge Fund | 0.9924 | 1561013 | 109439 | 2022-09-30 | LOW |
BlackRock Asset Management Ireland Limited | Investment Advisor | 0.9053 | 1424051 | 1354 | 2022-09-30 | LOW |
Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 0.8901 | 1400076 | 2726 | 2021-12-31 | LOW |
Hvorfor vælge Capital.com? Vores tal taler for sig selv.
Capital.com GroupHandlende
Månedlkige, aktive klienter
Månedlig investeringsvolumen
Hævet hver måned
Handelslommeregner
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Illumina Company profile
Om Illumina Inc
Illumina, Inc. er en leverandør af sekventerings- og array-baserede løsninger til genetisk og genomisk analyse. Virksomheden opererer gennem to segmenter: Core Illumina og GRAIL. Core Illumina-produkter og -tjenester betjener kunder på det forskningsmæssige, kliniske og anvendte marked og gør det muligt at indføre en række genomiske løsninger. GRAIL er en virksomhed inden for sundhedssektoren, der fokuserer på tidlig påvisning af flere forskellige kræftformer. Dens portefølje af integrerede sekventerings- og mikroarray-systemer, forbrugsvarer og analyseværktøjer er designet til genetisk analyse. Kunderne bruger dets platforme til at udføre sekventering af hele genomet, de novo-, exom- og ribonukleinsyre (RNA) sekventering og målrettet resequencing af specifikke genregioner og gener. Selskabets BeadArray-teknologi producerer arrays, der kan udføre mange analyser samtidig. Kunderne bruger selskabets array-baserede forbrugsmaterialer til genotypebestemmelse til en række analyser, herunder forskellige arter, sygdomsrelaterede mutationer og genetiske egenskaber i forbindelse med kræft.
Industry: | Advanced Medical Equipment & Technology (NEC) |
5200 Illumina Way
SAN DIEGO
CALIFORNIA 92122
US
Resultatopgørelse
- Annual
- Quarterly
Folk ser også
Leder du stadig efter en mægler, du kan stole på?
Deltag sammen med 485.000+ handlende over hele verden, der valgte at handle hos Capital.com